Enovis Corporation (NYSE: ENOV) Stock Competitors & Peer Comparison
See ENOV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ENOV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ENOV | $18.16 | -1.63% | 1B | 5.20 | $3.49 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.98 | -0.31% | 174.7B | 19.38 | $5.21 | +2.46% |
| MDT | $89.50 | +0.97% | 114.5B | 16.18 | $5.53 | +3.22% |
| SYK | $275.31 | +1.08% | 105.6B | 20.57 | $13.39 | +1.27% |
| BSX | $44.11 | +0.43% | 65.6B | 14.23 | $3.10 | N/A |
| EW | $86.83 | +0.63% | 50B | 32.16 | $2.70 | N/A |
| DXCM | $86.68 | +0.07% | 32.7B | 33.99 | $2.55 | N/A |
| GEHC | $66.78 | +0.23% | 30.2B | 14.64 | $4.56 | +0.21% |
| PHG | $25.11 | +0.60% | 24.5B | 14.35 | $1.75 | +3.94% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
ENOV vs BSX-PA Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ENOV's ROE is -0.68%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ENOV is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
ENOV vs ABT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ABT trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ABT's P/E ratio is 19.38. In terms of profitability, ENOV's ROE is -0.68%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ABT's competition here
Medtronic plc (NYSE: MDT)
ENOV vs MDT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while MDT trades at $89.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas MDT's P/E ratio is 16.18. In terms of profitability, ENOV's ROE is -0.68%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ENOV vs SYK Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SYK trades at $275.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SYK's P/E ratio is 20.57. In terms of profitability, ENOV's ROE is -0.68%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ENOV is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ENOV vs BSX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BSX trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BSX's P/E ratio is 14.23. In terms of profitability, ENOV's ROE is -0.68%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ENOV vs EW Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, EW has a market cap of 50B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while EW trades at $86.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas EW's P/E ratio is 32.16. In terms of profitability, ENOV's ROE is -0.68%, compared to EW's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ENOV vs DXCM Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while DXCM trades at $86.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas DXCM's P/E ratio is 33.99. In terms of profitability, ENOV's ROE is -0.68%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ENOV is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ENOV vs GEHC Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while GEHC trades at $66.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas GEHC's P/E ratio is 14.64. In terms of profitability, ENOV's ROE is -0.68%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ENOV vs PHG Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PHG trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PHG's P/E ratio is 14.35. In terms of profitability, ENOV's ROE is -0.68%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ENOV vs ZBH Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ZBH trades at $91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ZBH's P/E ratio is 10.80. In terms of profitability, ENOV's ROE is -0.68%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ENOV vs ABMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ENOV's ROE is -0.68%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ENOV vs PEN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PEN trades at $319.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PEN's P/E ratio is 83.31. In terms of profitability, ENOV's ROE is -0.68%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ENOV vs SWAV Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ENOV's ROE is -0.68%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ENOV is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
ENOV vs SNN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SNN trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SNN's P/E ratio is 18.28. In terms of profitability, ENOV's ROE is -0.68%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ENOV vs BIO-B Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, ENOV's ROE is -0.68%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ENOV is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ENOV vs ALGN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ALGN trades at $145.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ALGN's P/E ratio is 13.22. In terms of profitability, ENOV's ROE is -0.68%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ENOV vs BIO Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BIO trades at $377.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BIO's P/E ratio is 40.70. In terms of profitability, ENOV's ROE is -0.68%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ENOV is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
ENOV vs GMED Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while GMED trades at $74.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas GMED's P/E ratio is 16.84. In terms of profitability, ENOV's ROE is -0.68%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
ENOV vs BRKR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BRKR trades at $63.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BRKR's P/E ratio is 31.80. In terms of profitability, ENOV's ROE is -0.68%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ENOV is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
ENOV vs MASI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas MASI's P/E ratio is 44.43. In terms of profitability, ENOV's ROE is -0.68%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
ENOV vs GKOS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while GKOS trades at $158.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas GKOS's P/E ratio is -184.31. In terms of profitability, ENOV's ROE is -0.68%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ENOV is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
ENOV vs BRKRP Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BRKRP trades at $469.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, ENOV's ROE is -0.68%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ENOV is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BRKRP's competition here
Insulet Corp. (NASDAQ: PODD)
ENOV vs PODD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PODD trades at $133.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PODD's P/E ratio is 22.68. In terms of profitability, ENOV's ROE is -0.68%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ENOV is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
ENOV vs HAE Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while HAE trades at $105.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas HAE's P/E ratio is 21.13. In terms of profitability, ENOV's ROE is -0.68%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ENOV vs NARI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NARI's P/E ratio is -59.24. In terms of profitability, ENOV's ROE is -0.68%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ENOV is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ENOV vs ITGR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ITGR trades at $126.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ITGR's P/E ratio is 19.90. In terms of profitability, ENOV's ROE is -0.68%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ENOV is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
ENOV vs LIVN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while LIVN trades at $77.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas LIVN's P/E ratio is 18.34. In terms of profitability, ENOV's ROE is -0.68%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ENOV is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ENOV vs IRTC Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while IRTC trades at $112.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas IRTC's P/E ratio is -261.86. In terms of profitability, ENOV's ROE is -0.68%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ENOV is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ENOV vs AXNX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ENOV's ROE is -0.68%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AXNX's competition here
Neogen Corporation (NASDAQ: NEOG)
ENOV vs NEOG Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NEOG trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NEOG's P/E ratio is 49.00. In terms of profitability, ENOV's ROE is -0.68%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ENOV is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ENOV vs TMDX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while TMDX trades at $82.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas TMDX's P/E ratio is 41.99. In terms of profitability, ENOV's ROE is -0.68%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ENOV is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check TMDX's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ENOV vs BFLY Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BFLY trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BFLY's P/E ratio is -38.10. In terms of profitability, ENOV's ROE is -0.68%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ENOV is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ENOV vs AXGN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AXGN trades at $43.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AXGN's P/E ratio is 114.11. In terms of profitability, ENOV's ROE is -0.68%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ENOV is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ENOV vs UFPT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while UFPT trades at $299.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas UFPT's P/E ratio is 30.56. In terms of profitability, ENOV's ROE is -0.68%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ENOV is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ENOV vs NUVA Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ENOV's ROE is -0.68%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ENOV is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ENOV vs INSP Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while INSP trades at $70.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas INSP's P/E ratio is 30.84. In terms of profitability, ENOV's ROE is -0.68%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ENOV is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ENOV vs ESTA Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ESTA trades at $65.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ESTA's P/E ratio is -51.86. In terms of profitability, ENOV's ROE is -0.68%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ENOV is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
ENOV vs NVCR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NVCR trades at $15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NVCR's P/E ratio is -12.18. In terms of profitability, ENOV's ROE is -0.68%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ENOV is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ENOV vs ATEC Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ATEC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ATEC's P/E ratio is -167.50. In terms of profitability, ENOV's ROE is -0.68%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ENOV is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
ENOV vs CNMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CNMD trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CNMD's P/E ratio is 10.20. In terms of profitability, ENOV's ROE is -0.68%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ENOV is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
ENOV vs HSKA Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ENOV's ROE is -0.68%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ENOV vs IART Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while IART trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas IART's P/E ratio is 6.89. In terms of profitability, ENOV's ROE is -0.68%, compared to IART's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ENOV vs AVNS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ENOV's ROE is -0.68%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ENOV is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ENOV vs TNDM Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while TNDM trades at $16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas TNDM's P/E ratio is -17.66. In terms of profitability, ENOV's ROE is -0.68%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ENOV is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ENOV vs SILK Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SILK's P/E ratio is -18.96. In terms of profitability, ENOV's ROE is -0.68%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
ENOV vs AORT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AORT trades at $22.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AORT's P/E ratio is 38.23. In terms of profitability, ENOV's ROE is -0.68%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ENOV is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
ENOV vs IRMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while IRMD trades at $86.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas IRMD's P/E ratio is 43.55. In terms of profitability, ENOV's ROE is -0.68%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ENOV is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
ENOV vs FNA Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas FNA's P/E ratio is -19.83. In terms of profitability, ENOV's ROE is -0.68%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ENOV vs PRCT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PRCT trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PRCT's P/E ratio is -8.89. In terms of profitability, ENOV's ROE is -0.68%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ENOV is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ENOV vs LMRI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while LMRI trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas LMRI's P/E ratio is -19.74. In terms of profitability, ENOV's ROE is -0.68%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ENOV is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
ENOV vs BVS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BVS trades at $14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BVS's P/E ratio is 18.45. In terms of profitability, ENOV's ROE is -0.68%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ENOV is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ENOV vs CBLL Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CBLL trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CBLL's P/E ratio is -13.93. In terms of profitability, ENOV's ROE is -0.68%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ENOV is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ENOV vs BBNX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BBNX trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BBNX's P/E ratio is -12.44. In terms of profitability, ENOV's ROE is -0.68%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ENOV is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ENOV vs CSII Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CSII's P/E ratio is -20.83. In terms of profitability, ENOV's ROE is -0.68%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ENOV is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ENOV vs SIBN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SIBN trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SIBN's P/E ratio is -55.18. In terms of profitability, ENOV's ROE is -0.68%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ENOV is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
ENOV vs INMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while INMD trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas INMD's P/E ratio is 9.86. In terms of profitability, ENOV's ROE is -0.68%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ENOV vs VREX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas VREX's P/E ratio is 19.43. In terms of profitability, ENOV's ROE is -0.68%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ENOV is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ENOV vs AHCO Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AHCO trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AHCO's P/E ratio is 11.53. In terms of profitability, ENOV's ROE is -0.68%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ENOV is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ENOV vs AVR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while AVR trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas AVR's P/E ratio is -3.99. In terms of profitability, ENOV's ROE is -0.68%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ENOV is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ENOV vs CTKB Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CTKB trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CTKB's P/E ratio is -30.41. In terms of profitability, ENOV's ROE is -0.68%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ENOV is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ENOV vs SRDX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ENOV's ROE is -0.68%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ENOV vs KIDS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while KIDS trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas KIDS's P/E ratio is -19.14. In terms of profitability, ENOV's ROE is -0.68%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ENOV is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ENOV vs APEN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas APEN's P/E ratio is -9.43. In terms of profitability, ENOV's ROE is -0.68%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ENOV vs SSII Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SSII's P/E ratio is -48.17. In terms of profitability, ENOV's ROE is -0.68%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ENOV is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ENOV vs DCTH Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while DCTH trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, ENOV's ROE is -0.68%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ENOV is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ENOV vs ZIMV Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ENOV's ROE is -0.68%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ZIMV's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ENOV vs PACB Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PACB trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PACB's P/E ratio is -4.17. In terms of profitability, ENOV's ROE is -0.68%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ENOV is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check PACB's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ENOV vs TCMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while TCMD trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas TCMD's P/E ratio is 21.13. In terms of profitability, ENOV's ROE is -0.68%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ENOV is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ENOV vs SGHT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SGHT trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SGHT's P/E ratio is -16.55. In terms of profitability, ENOV's ROE is -0.68%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ENOV is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
ENOV vs CERS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CERS trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CERS's P/E ratio is -81.40. In terms of profitability, ENOV's ROE is -0.68%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ENOV is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ENOV vs NPCE Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NPCE trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NPCE's P/E ratio is -24.82. In terms of profitability, ENOV's ROE is -0.68%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ENOV is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ENOV vs CLPT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CLPT trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CLPT's P/E ratio is -12.97. In terms of profitability, ENOV's ROE is -0.68%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ENOV is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ENOV vs SENS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SENS trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SENS's P/E ratio is -4.41. In terms of profitability, ENOV's ROE is -0.68%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ENOV is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ENOV vs OFIX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while OFIX trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas OFIX's P/E ratio is -6.41. In terms of profitability, ENOV's ROE is -0.68%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ENOV is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ENOV vs CV Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CV trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CV's P/E ratio is -10.98. In terms of profitability, ENOV's ROE is -0.68%, compared to CV's ROE of -1.78%. Regarding short-term risk, ENOV is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ENOV vs SMLR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ENOV's ROE is -0.68%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ENOV vs TMCI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while TMCI trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas TMCI's P/E ratio is -4.77. In terms of profitability, ENOV's ROE is -0.68%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ENOV is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ENOV vs RCEL Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while RCEL trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas RCEL's P/E ratio is -8.10. In terms of profitability, ENOV's ROE is -0.68%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ENOV is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check RCEL's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ENOV vs CATX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while CATX trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas CATX's P/E ratio is -1.89. In terms of profitability, ENOV's ROE is -0.68%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ENOV is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ENOV vs TLSI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while TLSI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas TLSI's P/E ratio is -2.61. In terms of profitability, ENOV's ROE is -0.68%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ENOV is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ENOV vs INFU Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while INFU trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas INFU's P/E ratio is 31.35. In terms of profitability, ENOV's ROE is -0.68%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ENOV vs MGRM Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ENOV's ROE is -0.68%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
ENOV vs ELMD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ELMD trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ELMD's P/E ratio is 21.51. In terms of profitability, ENOV's ROE is -0.68%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ENOV is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
ENOV vs NVRO Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ENOV's ROE is -0.68%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ENOV is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
ENOV vs PROF Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while PROF trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas PROF's P/E ratio is -6.04. In terms of profitability, ENOV's ROE is -0.68%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ENOV is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
ENOV vs RXST Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while RXST trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas RXST's P/E ratio is -4.13. In terms of profitability, ENOV's ROE is -0.68%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ENOV is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ENOV vs BSGM Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ENOV's ROE is -0.68%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ENOV is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ENOV vs MDGS Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ENOV's ROE is -0.68%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ENOV is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ENOV vs STIM Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while STIM trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas STIM's P/E ratio is -5.81. In terms of profitability, ENOV's ROE is -0.68%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ENOV is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ENOV vs FOCL Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while FOCL trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas FOCL's P/E ratio is -4.38. In terms of profitability, ENOV's ROE is -0.68%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ENOV is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
ENOV vs QTRX Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while QTRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas QTRX's P/E ratio is -1.39. In terms of profitability, ENOV's ROE is -0.68%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ENOV is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ENOV vs QIPT Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ENOV's ROE is -0.68%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check QIPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ENOV vs QSI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while QSI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas QSI's P/E ratio is -1.73. In terms of profitability, ENOV's ROE is -0.68%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ENOV is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check QSI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ENOV vs LUCD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while LUCD trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas LUCD's P/E ratio is -2.18. In terms of profitability, ENOV's ROE is -0.68%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ENOV is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
ENOV vs INGN Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while INGN trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas INGN's P/E ratio is -5.98. In terms of profitability, ENOV's ROE is -0.68%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ENOV is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
ENOV vs ICAD Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ENOV's ROE is -0.68%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ENOV is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
ENOV vs ECOR Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ECOR trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ECOR's P/E ratio is -6.57. In terms of profitability, ENOV's ROE is -0.68%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, ENOV is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ENOV vs HJLI Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas HJLI's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.68%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ENOV is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
ENOV vs ASXC Comparison September 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ENOV is priced at $18.16 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 5.20, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ENOV's ROE is -0.68%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ENOV is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ASXC's competition here